SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Nieuweboer Annemieke J. M.)
 

Sökning: WFRF:(Nieuweboer Annemieke J. M.) > Association between...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00004780naa a2200493 4500
001oai:DiVA.org:uu-380502
003SwePub
008190423s2019 | |||||||||||000 ||eng|
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-3805022 URI
0247 a https://doi.org/10.3390/cancers110201732 DOI
040 a (SwePub)uu
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Toxopeus, Eelke L. A.u Erasmus Univ, Med Ctr, Dept Surg, Doctor Molewaterpl 40, NL-3015 GD Rotterdam, Netherlands4 aut
2451 0a Association between Paclitaxel Clearance and Tumor Response in Patients with Esophageal Cancer
264 c 2019-02-01
264 1b MDPI,c 2019
338 a electronic2 rdacarrier
520 a Inter-individual variability in paclitaxel pharmacokinetics may play a role in the response to chemotherapy. Therefore, we studied the association between paclitaxel clearance and treatment response in patients with esophageal cancer. All patients who received paclitaxel (plus carboplatin) treatment for esophageal cancer between 2007 and 2013 were included. The treatment was given as neoadjuvant chemoradiotherapy (nCRT), induction chemotherapy (iCT), or palliative chemotherapy (pCT). The treatment response was assessed by the tumor regression grade (TRG) or by the RECIST1.1 criteria, respectively. The unbound paclitaxel clearance (CL) was estimated with NONMEM. The log-transformed clearance was related to response with ANOVA and independent sample t-tests. A total of 166 patients were included, of whom 113 received nCRT, 23 iCT and 30 pCT. In patients receiving nCRT, paclitaxel clearance was not associated with tumor regression grade (p-value = 0.25), nor with pathologically complete response (geometric mean 561.6 L/h) and residual disease (geometric mean 566.1 L/h, p-value = 0.90). In patients who underwent iCT or pCT, also no association between paclitaxel clearance and RECIST outcome was identified (iCT: p-value = 0.08 and pCT: p-value = 0.81, respectively). In conclusion, systemic paclitaxel exposure was not associated with response to common paclitaxel-based treatment regimens for esophageal cancer. Future studies should focus on tumor exposure in relation to systemic exposure and treatment outcome.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
653 a paclitaxel
653 a esophageal cancer
653 a treatment response
653 a pharmacokinetics
7001 a de Man, Femke M.u Erasmus Univ, Erasmus Med Ctr, Med Ctr, Canc Inst,Dept Med Oncol, Doctor Molewaterpl 40, NL-3015 GD Rotterdam, Netherlands4 aut
7001 a Krak, Nandau Erasmus Univ, Med Ctr, Dept Radiol, Doctor Molewaterpl 40, NL-3015 GD Rotterdam, Netherlands4 aut
7001 a Biermann, Katharinau Erasmus Univ, Med Ctr, Dept Pathol, Doctor Molewaterpl 40, NL-3015 GD Rotterdam, Netherlands4 aut
7001 a Nieuweboer, Annemieke J. M.u Erasmus Univ, Erasmus Med Ctr, Med Ctr, Canc Inst,Dept Med Oncol, Doctor Molewaterpl 40, NL-3015 GD Rotterdam, Netherlands4 aut
7001 a Friberg, Lena E.u Uppsala universitet,Institutionen för farmaceutisk biovetenskap4 aut0 (Swepub:uu)lenasimo
7001 a Oomen-de Hoop, Estheru Erasmus Univ, Erasmus Med Ctr, Med Ctr, Canc Inst,Dept Med Oncol, Doctor Molewaterpl 40, NL-3015 GD Rotterdam, Netherlands4 aut
7001 a van Lanschot, Jan J. B.u Erasmus Univ, Med Ctr, Dept Surg, Doctor Molewaterpl 40, NL-3015 GD Rotterdam, Netherlands4 aut
7001 a Shapiro, Joelu Erasmus Univ, Med Ctr, Dept Surg, Doctor Molewaterpl 40, NL-3015 GD Rotterdam, Netherlands4 aut
7001 a Wijnhoven, Bas P. L.u Erasmus Univ, Med Ctr, Dept Surg, Doctor Molewaterpl 40, NL-3015 GD Rotterdam, Netherlands4 aut
7001 a Mathijssen, Ron H. J.u Erasmus Univ, Erasmus Med Ctr, Med Ctr, Canc Inst,Dept Med Oncol, Doctor Molewaterpl 40, NL-3015 GD Rotterdam, Netherlands4 aut
7102 a Erasmus Univ, Med Ctr, Dept Surg, Doctor Molewaterpl 40, NL-3015 GD Rotterdam, Netherlandsb Erasmus Univ, Erasmus Med Ctr, Med Ctr, Canc Inst,Dept Med Oncol, Doctor Molewaterpl 40, NL-3015 GD Rotterdam, Netherlands4 org
7730 t Cancersd : MDPIg 11:2q 11:2x 2072-6694
8564 u https://doi.org/10.3390/cancers11020173y Fulltext
8564 u https://uu.diva-portal.org/smash/get/diva2:1306425/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print
8564 u https://www.mdpi.com/2072-6694/11/2/173/pdf
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-380502
8564 8u https://doi.org/10.3390/cancers11020173

Hitta via bibliotek

  • Cancers (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy